September 18, 2025
FOCUS on Neuroblastoma. In a paper just out in Nature Communications, Singh et al. report: “To better understand the cellular plasticity of neuroblastoma in chemoresistance, we […]
September 4, 2025
FOCUS on Drug Approvals. On August 6 the FDA granted accelerated approval to Jazz Pharmaceuticals’ Dordaviprone (TIC10 or ONC-201) for patients with diffuse midline glioma harboring […]
August 16, 2025
FOCUS on Drug Approvals. On August 8 the FDA granted accelerated approval to Boehringer Ingelheim’s Zongertinib (BI 1810631) for adults with unresectable or metastatic non-squamous non-small […]
July 28, 2025
FOCUS on Clinical Trials. Today Celcuity announced the results of a Phase-3 clinical trial of Gedatolisib plus fulvestrant in patients with HR-positive, HER2-negative, PIK3CA wild-type locally […]
July 21, 2025
FOCUS on New Drug Targets: Epithelial-to-mesenchymal (EMT) transition is widely recognized as a cell-intrinsic process that augments the metastatic potential of cancer cells by enhancing motility […]
June 26, 2025
FOCUS on Drug Approvals. On June 23rd, the FDA approved datopotamab deruxtecan-dlnk (AstraZeneca and Daiichi Sankyo’s Datroway) for non-small cell lung cancer. The antibody-drug conjugate (or […]
June 19, 2025
FOCUS on Drug Approvals. On June 11th, the FDA approved Taletrectinib (Ibtrozi, Nuvation Bio Inc) for adults with locally advanced or metastatic, ROS1-positive, non-small cell lung […]
April 21, 2025
Focus Biomolecules will be exhibiting at the annual meeting of American Association for Cancer Research in Chicago, April 27 – 30. Stop by our booth (#1004) […]
March 6, 2025
Focus on Drug Discovery. Lilly will acquire Scorpion Therapeutics’ PI3Kalpha inhibitor program which includes STX-478, a potentially best-in-class mutant-selective PI3Kα inhibitor currently being evaluated in a […]